Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short-term Investments (2017 - 2025)

Coherus Oncology (CHRS) has disclosed Short-term Investments for 8 consecutive years, with $83.2 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments changed N/A to $83.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $83.2 million for FY2025, N/A changed from the prior year.
  • Short-term Investments hit $83.2 million in Q4 2025 for Coherus Oncology, down from $88.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $140.0 million in Q1 2021 to a low of $8000.0 in Q2 2023.
  • Historically, Short-term Investments has averaged $79.2 million across 4 years, with a median of $88.3 million in 2025.
  • Biggest five-year swings in Short-term Investments: plummeted 46.23% in 2021 and later crashed 88.41% in 2023.
  • Year by year, Short-term Investments stood at $108.2 million in 2021, then rose by 18.46% to $128.1 million in 2022, then plummeted by 88.41% to $14.9 million in 2023, then skyrocketed by 460.32% to $83.2 million in 2025.
  • Business Quant data shows Short-term Investments for CHRS at $83.2 million in Q4 2025, $88.3 million in Q3 2025, and $20.7 million in Q2 2025.